Načítá se...
Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds
Introduction. Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results. However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today. Aim. To assess the cost of treatment with NXB...
Uloženo v:
| Vydáno v: | Biomed Res Int |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Hindawi Publishing Corporation
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5331316/ https://ncbi.nlm.nih.gov/pubmed/28293640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/9567498 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|